Federal Circuit Reverses District Court’s Denial of JMOL and Finds That Semiconductor Patent Was Not Enabled Under 35 U.S.C. § 112

Aug 7, 2018

Reading Time : 2 min

The ’738 patent relates to the field of light-emitting diodes (LEDs), which are semiconductor devices that typically consist of multiple layers of solid-state materials. Claim 19, the only claim-at-issue, is directed to a semiconductor device that includes a growth layer “grown on” a non-single crystalline buffer layer. During claim construction, plaintiff-cross-appellant Boston University (BU) successfully argued that “grown on” meant “formed indirectly or directly above” the buffer layer and that “non-single crystalline buffer layer” meant a layer of material that is not monocrystalline. Based on this construction, Clamim 19 provided for six possible combinations of a growth layer and a buffer layer. The enablement issue here centered on whether the ’738 patent taught one of those combinations, namely, a monocrystalline growth layer formed directly on an amorphous buffer layer.

The defendant-appellants–Everlight, Epistar and Lite-On (collectively, “Defendants”) –argued that Claim 19 is not enabled because the ’738 patent’s specification does not teach one of skill in the art how to make the claimed semiconductor device with a monocrystalline growth layer grown directly on an amorphous buffer layer through epitaxy. In fact, Defendants’ expert testified that it is impossible to epitaxially grow a monocrystalline film directly on an amorphous structure, a statement with which BU’s expert agreed. Based on the expert testimony, the Federal Circuit concluded, “the specification does not enable what the experts agree is physically impossible.”

BU attempted to sidestep this shortcoming by arguing that the ’738 patent teaches other ways to grow a monocrystalline layer directly on an amorphous layer. The Federal Circuit rejected BU’s argument, noting that BU could not identify any passage of the specification that discloses how to grow a monocrystalline layer directly on an amorphous layer.

BU also pointed to testimony indicating that others have successfully grown a monocrystalline layer directly on an amorphous buffer layer. The district court acknowledged that the testing occurred after the ’738 issued, but admitted the evidence to rebut the argument that such growth was impossible. The Federal Circuit found this evidence to be nonprobative of enablement, reasoning that “[t]he inquiry is not whether it was, or is, possible to make the full scope of the claimed device . . . . The inquiry is whether the patent’s specification taught one of skill in the art how to make such a device without undue experimentation as of the patent’s effective filing date.”  Therefore, “[s]imply observing that it could be done—years after the patent’s effective filing date—bears little on the enablement inquiry.”

The court concluded that, “to some extent, BU created its own enablement problem” by seeking a specific claim construction, but failing to defend against an enablement challenge as to the claim’s full scope. That is, “if BU wanted to exclude others from what it regarded as its invention, its patent needed to teach the public how to make and use that invention. That is part of the quid pro quo of the patent bargain.”

Practice Tip:  Be careful what you wish for. This case provides a good example of how a successful argument in favor of a broad claim construction may backfire on a plaintiff if the patent fails to enable the full scope of the broad construction.

Trustees of Boston University. v. Everlight Electronics Co., Ltd., Everlight Americas, Inc., Epistar Corporation, Lite-On Inc., Lite-On Service USA, Inc., Lite-On Technology Corporation, Lite-On Trading USA, Inc., Nos. 2016-2576, 2016-2577, 2016-2578, 2016-2579, 2016-2580, 2016-2581, 2016-2582, 2016-2591, 2016-2592, 2016-2593, 2016-2594, 2016-2595 (Fed. Cir. July 25, 2018

Share This Insight

Categories

Previous Entries

IP Newsflash

October 1, 2025

In a recent final written decision, the PTAB determined that a reference patent was not prior art, despite the petitioner’s post‑filing attempt to correct its petition. While the petitioner argued that it intended to rely on the patent application’s earlier date of publication, both the corrected petition and the expert declaration continued to reference the issued patent rather than the published application.

...

Read More

IP Newsflash

September 30, 2025

The USPTO Director recently granted a petitioner’s request for rehearing of the decision discretionarily denying institution of inter partes review, ultimately vacating the original decision, and referring the petition to the board for an institution decision.

...

Read More

IP Newsflash

September 25, 2025

In considering claims to a method of reducing cardiovascular events, the Federal Circuit held that the term a “clinically proven effective” amount did not render the claims patentable over the prior art. Specifically, the Federal Circuit held that the “clinically proven effective” amount, whether limiting or not, could not be used to distinguish the prior art because the claims also specified the exact amount of the drugs to be administered in the method. The Federal Circuit also rejected patentee’s evidence of unexpected results because that evidence was tied solely to the “clinically proven effective” limitation.

...

Read More

IP Newsflash

September 24, 2025

The Federal Circuit reversed a district court’s denial of judgment as a matter of law on non-infringement, thereby setting aside a $106 million jury verdict, after holding that prosecution history estoppel barred the patentee from asserting infringement under the doctrine of equivalents.

...

Read More

IP Newsflash

September 17, 2025

A magistrate judge in the District of Delaware issued a Report and Recommendation, that found the sole asserted claim was a “single means” claim and therefore invalid for lack of enablement. In reaching that conclusion, the magistrate judge rejected the patentee’s argument that the preamble of the claim disclosed a second element that satisfied the combination requirement of Section 112, paragraph 6 because the preamble simply recited a descriptor of the very apparatus that was the subject of the means-plus-function limitation in the body of the claim. The district court judge presiding over this case has scheduled a hearing to review the magistrate’s ruling.

...

Read More

IP Newsflash

September 9, 2025

The Federal Circuit has affirmed the PTAB’s determination that a patent challenger did not show the challenged claims were unpatentable for obviousness. The Federal Circuit concluded that substantial evidence, which included expert testimony, showed there was no motivation to combine the references.

...

Read More

IP Newsflash

August 29, 2025

In a recent order addressing four IPR proceedings, the PTAB exercised its inherent authority under 37 C.F.R. § 42.5(a) to sua sponte authorize post-hearing discovery on a potentially dispositive privity issue. The order followed a Director review decision that vacated and remanded earlier IPRs involving the same parties, patent family, and privity issue. 

...

Read More

IP Newsflash

August 29, 2025

The Patent Trial and Appeal Board denied institution of an inter partes review petition in part because it determined that a patent reference was not prior art under the common ownership exception of pre-AIA 35 U.S.C. § 103(c)(1).

...

Read More

© 2025 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.